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Abstract: MicroRNAs (miRNAs) are short, noncoding, and single-stranded RNA molecules that negatively regulate gene 
expression. They are evolutionarily conserved from plants to animals. During the last decade, miRNAs have been demon-
strated as regulators in fundamental biological processes, including cell growth, proliferation, differentiation and apopto-
sis. By base pairing to the complementary sites in the mRNA of the target gene, miRNA can lead to repression of protein 
translation or cleavage of mRNA. Among over 700 miRNAs identified in the human genome, several of them were con-
firmed as ‘oncomirs’, which denote miRNAs associated with initiation and progression of cancers. Generally, depending 
on their target genes, these miRNAs function as tumor suppressors or oncogenes. However, the miR-17-92 cluster in the 
human genome, which encodes 7 mature microRNAs, has been validated as regulator showing both oncogenic and tumor 
suppressive properties. The miR-17-92 cluster targets mRNAs involved in distinct pathways so that it may exert opposing 
effects. The transcription factors E2Fs and c-Myc, which play critical roles in tumorigenesis, could interact with the clus-
ter. The feedback loops, which are comprised of the transcription factors and the miR-17-92 cluster, weave a complex 
regulation net work of cancers. The duality of this cluster reflects the complexities of cancer progressions as well as the 
intricacies of the regulation network of miRNAs and their targets. With the help of the development of new experimental 
methods and bioinformatics, further researches on the miR-17-92 cluster and other oncomirs will give new insights into 
cancer diagnosis, therapy, and prognosis. 
Received on: November 15, 2009 - Revised on: December 25, 2009 - Accepted on: January 06, 2010 
Keywords: microRNAs (miRNAs), the miR-17-92 cluster, oncomir, cancer, siRNAs, c-Myc, E2Fs. 
INTRODUCTION 
  MicroRNAs (miRNAs) are a family of endogenous, non-
coding, and single-stranded RNA molecules of 17-~27-
nucleotides in length that regulate gene expression posttran-
scriptionally [1]. The first miRNA, lin-4, was identified in 
1993 [2]. Ambros and colleagues confirmed that using an 
antisense complemental mechanism, a novel 22-nucleotide 
small RNA encoded by lin-4 repressed the expression of lin-
14 protein. This downregulation led to the change of tempo-
ral pattern formation in Caenorhabditis elegans [3]. This 
finding was considered as a genetic oddity in C. elegans, 
therefore, little attention was paid to this small RNA. In 
2000, Reinhart et al. discovered the second miRNA, let-7, 
which was also involved in C. elegans development [4]. Re-
searchers found that the sequence and temporal expression of 
let-7 were conserved in a wide range of animal species, in-
cluding vertebrate [5]. The “novelty” soon became the “har-
binger”. Since then, thousands of miRNAs have been identi-
fied in various species, such as plants [6], worms [7-10], 
flies [11, 12] and mammals [13, 14].  
  Owing to the development of biochemical searches and 
informatic analysis during the last decade, researchers 
around the world have published numerous stories in high-
profile magazines to unveil the big roles played by these tiny 
molecules. The explosion of miRNAs research has propelled 
the discoveries that miRNAs are of great importance in   
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fundamental biological processes, including development 
[15, 16, 17], cellular growth, proliferation, apoptosis, glu-
cose and lipid metabolism [18], viral infection [19], insulin 
secretion [20] and immune response [21]. To date, in the 
human genome, 721 miRNAs have been annotated in the 
miRBase (http://microrna.sanger.ac.uk/sequences/). How-
ever, they do not include the whole human miRNAome, it is 
estimated that the final number is probably over 1,000. [22, 
23, 24] 
  As miRNAs play pivotal roles in multiple biological 
processes, aberrant expression of this family of regulators 
might result in human diseases. In this review, we mainly 
focus on the association between miRNAs and cancers, the 
role of the miR-17-92 cluster in tumorigenesis, and potential 
applications of miRNAs in cancer diagnosis, therapy and 
prognosis. 
MicroRNAs BIOGENESIS 
  The biogenesis pathway of miRNAs in animals was elu-
cidated by Bartel et al. in 2004 [16]. Fig. (1) shows the 
pathway briefly. Some microRNAs come from distinct tran-
scription units, while some other microRNA genes are clus-
tered in the genome [16]. Usually, there are two or three 
miRNA genes in a cluster, however, larger clusters including 
more miRNA genes have also been identified. For example, 
the miR-17-92 cluster, whose function will be elaborated in 
the following paragraphs, is composed of seven miRNA 
genes [25]. MiRNA is transcribed by RNA polymerase  in 
nucleus, this early large transcript termed pri-miRNA is 
capped and polyadenylated. Then the pri-miRNA is proc-130    Current Genomics, 2010, Vol. 11, No. 2  Xiang and Wu 
essed by the Drosha RNase  endonuclease, and the cleav-
age usually liberates the pre-miRNA, which is ~75-
nucleotides in length with stem loop. This step is critical and 
a double-stranded-RNA-binding protein, called DGCR8 in 
mammals, is needed for processing [26]. Sequentially, the 
pre-miRNA is exported to the cytoplasm by Ran-GTP and 
the transporter Exportin-5. In the cytoplasm, pre-miRNA is 
processed by the ribonuclease Dicer, which is also RNase  
endonuclease and plays a similar role in the biogenesis of 
short interfering RNAs (siRNAs). Dicer cuts both strands of 
the precursor, leaving a double-stranded (ds) RNA molecule 
of approximately 22-nucleotides in length. The molecule is 
called the miRNA:miRNA* duplex and is composed of ma-
ture miRNA strand and the sequences derived from the op-
posing arm. The duplex is a transient intermediate during the 
biogenesis. After processing, the active strand of the duplex 
assembles into the RNA-induced silencing complex (RISC), 
while the miRNA*, which is the inactive strand, is ejected 
and degraded. The mature miRNA incorporated into the 
RISC binds to the complementary sites in the mRNA of the 
target gene. Argonaute (Ago) proteins are indispensable 
components of the RISC and play critical part in the post-
transcriptional gene silencing (PTGS). The complementarity 
of the miRNA and the mRNA usually leads to mRNA cleav-
age or translational repression. Perfect or near-perfect com-
plementarity is required for mRNA cleavage, whereas the 
lower degree of complementarity results in translational re-
pression. In the animals, the latter mechanism is more preva-
lent.  
  SiRNAs are a class of double-stranded RNAs originated 
from long and perfectly base-paired dsRNA, which can also 
direct PTGS. Since Fire and Mello discovered this gene si-
lencing pathway in 1998 [27], siRNAs have been intriguing 
not only as an efficient experimental tool to uncover the gene 
function but also as a potential remedy for diseases. Al-
though miRNAs and siRNAs share similar molecular charac-
teristics, biogenesis and functions [28], there are some no-
ticeable distinctions between these two families of small 
RNAs [16, 26]. Besides the differences in biogenesis path-
ways, siRNAs silence almost exclusively the same locus 
from which they are produced (auto-silencing), whereas 
miRNAs silence genes different from which their primary 
transcripts originate (hetero-silencing). In related organisms, 
the degree of the sequence conservation of miRNAs is 
greater than that of siRNAs. SiRNA-mediated gene silencing 
represents an evolutionarily conserved method of genome 
defense against exogenous nucleic acids, such as virus, 
transgenes and transposons [29]. However, as described ear-
lier, miRNAs function as essential regulators in fundamental 
biological processes in organisms.  
ONCOMIRS AND TUMORIGENESIS 
  Recent evidences indicate that miRNAs can function as  
tumor suppressors and oncogenes, and these miRNAs are   
referred to as ‘oncomirs’ [17, 30, 31]. When cells are dam- 
aged, uncontroled proliferation and inappropriate survival of  
these cells might lead to cancer. Oncogenes and tumor- 
suppressor genes are two pivotal factors in tumorigenesis. In  
normal tissue, proper regulation of miRNAs maintains a   
normal rate of development, cell growth, proliferation, dif- 
ferentiation and apoptosis. However, deregulation of miR- 
NAs target mRNAs of cancer-associated genes probably put  
cell in danger of canceration. If the target gene is an onco- 
gene, the loss of the miRNA, which functions as a tumor  
suppressor, might lead to a high expression level of the on- 
coprotein, therefore tumor formation is likely to happen. On  
the other hand, as to miRNA functions as an oncogene,   
constitutively amplification or overexpression of this   
miRNA could cause immoderate repression of its target   
gene, which has a role of tumor suppressor gene, thus, in this  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Overview of microRNAs biogenesis. MicroRNA is tran-
scribed as pri-miRNA in nucleus and then processed into pre-
miRNA by Drosha. After exportated to the cytoplasm, the pre-
miRNA is processed by Dicer into a small dsRNA called the 
miRNA:miRNA* duplex. The active strand, which is the mature 
miRNA is incorporated into the RISC and binds to the target 
mRNA, whereas the inactive strand is ejected and degraded. The 
complementarity of the miRNA and the mRNA leads to transla-
tional inhibition or mRNA cleavage. Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis  Current Genomics, 2010, Vol. 11, No. 2    131 
situation, cell is likely to confront the threat of tumorigenesis  
[30]. Using genome-wide mapping and northern blotting,   
researchers demonstrated that microRNA genes are fre- 
quently located at fragile sites, minimal regions of loss of  
heterozygosity, minimal regions of amplification (minimal   
amplicons) or other cancer-associated genomic regions [25].  
Furthermore, several research groups reported deregulations  
of miRNAs in cancer samples. MiR-15 and miR-16 are   
downregulated in 68% of chronic lymphocytic leukemia   
patients [32]. Michael and colleagues found that miR-143  
and miR-145 display reduced steady-state levels of the ma- 
ture miRNA at the adenomatous and cancer stages of colo- 
rectal neoplasia [33]. Reduced expression of let-7 in lung   
cancers has also been observed [33, 34]. Besides, evidences  
reveal microRNAs function as tumor suppressors, studies   
also show that some miRNAs play roles as oncogenes. For  
example, Chan et al. reported overexpression of miR-21 in  
glioblastoma tumor tissues and cell lines in human [35]. De- 
regulations of the miR-17-92 in different cancer samples   
have been reported frequently, and studies implicated that   
this cluster performs activity of oncogene as well as tumor  
suppressor. Thus, wide interest has been attracted to this   
especial microRNA cluster. 
THE miR-17-92 CLUSTER AND TUMORIGENESIS 
  A polycistronic microRNA cluster termed miR-17-92, 
located in chromosome 13 open reading frame 25 
(C13orf25) in the human genome, encodes seven miRNAs: 
miR-17-5p,  miR-17-3p,  miR-18a,  miR-19a,  miR-20a,  miR-
19b and miR-92-1. Fig. (2) shows the genomic organization 
of this cluster.  
The Oncogenic Role of the miR-17-92 Cluster 
  The amplification of 13q31-q32, which is the locus of the 
miR-17-92 cluster, have been reported in hematopoietic ma-
lignancies and other solid tumors [36], including diffuse 
large B-cell lymphoma (DLBCL), mantle cell lymphoma, 
follicular lymphoma, primary cutaneous B-cell lymphoma, 
nasal-type natural killer/T-cell lymphoma, glioma, non-small 
cell lung cancer, bladder cancer, squamous-cell carcinoma of 
the head and neck, peripheral nerve sheath tumor, malignant 
fibrous histiocytoma, alveolar rhabdomyosarcoma, liposar-
coma and colon carcinomas [36, 37, 38]. C13orf25 has been 
implicated by Ota et al. as the gene for the amplification of 
13q31-q32 in tumors [36]. Later, He and colleagues [39] 
observed significant overexpression of pri-miR-17-92 in 65% 
of human tumor samples. Five miRNAs of the cluster (miR-
92-1, miR-19a, miR-20a, miR-19b, miR-17-5p) were upregu-
lated in these cancer cell lines. To further test the role of the 
miR-17-92 cluster in tumorigenesis, they turned to a mouse 
B-cell lymphoma model. Enforced expression of the cluster 
accelerated the progression of malignant lymphomas in 
mice. Results indicate that the miR-17-92 cluster functions as 
an oncogene in a cooperative way acted with c-Myc, which 
is an oncogenic transcription factor often mutated or ampli-
fied in human cancers. Dysregulated expression of this on-
coprotein in human malignancy has been reported as one of 
the most common abnormalities [40]. Previous researches 
have shown that c-Myc could regulate cell growth by induc-
ing both cell proliferation and apoptosis [41]. As an absence 
of apoptosis was observed in the lymphomas derived from 
mice expressing both c-myc and miR-17-19b (a subset of the 
miR-17-92 cluster), the miR-17-92 cluster possibly targets 
apoptotic factors that are activated, when c-Myc is overex-
pressed [39]. Altogether, data from He et al. suggest an on-
cogenic role of miR-17-92 cluster and the researchers named 
the primary transcript for these miRNAs ‘OncomiR-1’ [39]. 
Therefore, the term ‘oncomir’ was coined to denote mi-
croRNA involved in the initiation and progression of can-
cers. Several members of the cluster are overexpressed sepa-
rately and simultaneously in human solid tumors, including 
cancers of breast, colon, lung, stomach, pancreas and pros-
tate [38]. Using chromatin immunoprecipitation (ChIP) as-
says, O’Donnell et al. confirmed that human c-Myc binds 
directly to the miR-17-92 cluster genomic locus on chromo-
some 13, providing strong evidence that the transcription of 
this cluster is directly induced by c-Myc [42]. E2F family of 
transcription factors, including E2F1, E2F2 and E2F3, have 
been reported to drive progression from G1 into S phase in 
mammalian cells by activating expression of genes involved 
in DNA replication and cell cycle control. Moreover, it has 
been validated that high levels of E2Fs, E2F1 in particular, 
can induce apoptosis in response to DNA damage [43]. The 
research group reported that E2F1 is negatively regulated by 
miR-17-5p and miR-20a. Since previous studies have sug-
gested that c-Myc and members of E2Fs can activate one 
another’s transcription, a tightly controled network is estab-
lished, through which c-Myc could activate the E2F1 tran-
scription and limit its translation simultaneously [42]. Fur-
thermore, several lines of evidence verified that the E2F 
transcription factors could induce the expression of miRNAs 
of the cluster, and two other members of E2Fs, E2F2 and 
E2F3 are targeted by the miR-17-92 cluster [44, 45]. Collec-
tively, a complex interaction network comprising of c-Myc, 
E2Fs and the miR-17-92 cluster is unraveled (Fig. (3)). In 
this regulatory network model, microRNAs of the cluster 
downregulate the E2Fs, as a result, the proapoptotic role of 
E2Fs is inhibited. Therefore, the miR-17-92 cluster exerts its 
oncogenic function through assisting the DNA-damaged cell 
in escaping the fate of programmed cell death.  
  Besides E2Fs, several other negative regulators of the G1-
S checkpoint or proapoptotic proteins are targeted by the 
miR-17-92  cluster. The expression of cyclin-dependent 
kinase inhibitor CDKN1A (p21) is inhibited by miR-17-5p, 
miR-18a, and miR-20a. Another member of the miR-17-92 
cluster, miR-92-1 could repress the expression level of the 
tumor suppressor gene, BIM, which has a role of proapopto-
sis [46, 47]. More recently, researchers observed that miR-
17-92 cluster could counterbalance the generation of DNA 
damage in RB-inactivated small-cell lung cancer (SCLC), 
which leads to genetic instability in this type of malignancy 
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[48]. The action of microRNAs in the process of angiogene-
sis, which is essential for tumor development and metastasis, 
should not be neglected. Dews et al. demonstrated that c-
Myc functions as an inducer of angiogenesis in solid tumors 
through activating the transcription of the miR-17-92 cluster, 
which downregulates anti-angiogenic proteins such as 
thrombospondin-1 (Tsp1) and connective tissue growth fac-
tor (CTGF) [49, 50]. The miR-17-92 cluster is highly ex-
pressed in mouse ES cells and chicken embryos, while the 
expression level of the cluster decreases in differentiated 
tissues [51, 52]. Loss of differentiation and uncontrollable 
proliferation are two major characteristics of cancer, and 
mounting evidence indicates that cancer stem cell model is 
responsible for cancerogenesis [53], thus, the “stemness” of 
this cluster suggests a correlation between high level expres-
sion of the miR-17-92 cluster in cancer samples and continu-
ous self-renewal of cancer stem cells [54].  
The Tumor Suppressive Role of the miR-17-92 Cluster 
   Accumulating evidences indicate the oncogenic role of 
the miR-17-92 cluster, paradoxically, researchers observed 
that the cluster could act as a tumor suppressor in some cir-
cumstances. Loss of heterozygosity at 13q12-q13 is associ-
ated with multiple tumor progression and poor prognosis, 
including breast cancer, squamous cell carcinoma of the lar-
ynx, retinoblastoma, hepatocellular carcinoma and naso-
pharyngeal carcinoma [55]. Using a high-resolution array-
based comparative genomic hybridization in human tumor 
specimens, Zhang et al. observed the miR-17-92 cluster was 
deleted in 16.5% of ovarian cancers, 21.9% of breast can-
cers, and 20.0% of melanomas [56]. As described earlier, c-
Myc induces expression of the E2Fs, which drive progres-
sion from G1 into S phase in cells. In this circumstance, the 
transition promotes the proliferation of cells, so that E2Fs 
functions as oncogenic proteins. Thus, the miR-17-92 cluster, 
which downregulates E2Fs, may serve as a brake on exces-
sive proliferation. As a consequence, the cluster performs the 
anti-tumorigenic activity. The miR-17-5p exerts its role of 
tumor suppressor in breast cancer cells by repressing the 
expression of AIB1 (named for “amplified in breast cancer 
1”). Overexpression or downregulation of the miR-17-5p 
could suppress or promote breast cancer cell proliferation, 
respectively [57]. Recently, Yu et al. reported that Cyclin 
D1, which has been demonstrated as an oncogenic protein in 
breast cancer cell, is negatively regulated by miR-17-5p and 
miR-20a [58].  
Clues to Unravel the Paradox 
 Table  1. summarizes functions of the targets of the miR- 
17-92 cluster mentioned above. The fact that miR-17-92  
cluster functions both as oncogenes and tumor suppressors,  
implicates the complexities of cancer progressions as well as  
the intricacies of the regulation network of miRNAs. A sin- 
gle miRNA could target hundreds of mRNAs involved in   
distinct pathways, thus it may perform opposing functions.  
By using web-based Ingenuity Pathways Analysis (IPA),   
Cloonan and colleagues uncovered a large genetic network  
in which the miR-17-5p is a key regulator of the G1/S phase  
cell cycle transition [59]. More than 20 genes involved in the  
transition between the G1/S phase are directly targeted by   
this single microRNA. MiR-17-5p can exert both oncogenic  
and tumor suppressive function through decreasing the ex- 
pression levels of anti-proliferative genes and pro- 
proliferative genes, respectively. These findings reflect that a  
single miRNA acts opposing roles in order to maintain equi- 
librium in vivo. Perhaps the role of the miR-17-92 cluster as  
oncogene or tumor suppressor is dependent on the cell type  
and the expression pattern and levels of the target mRNAs  
[59]. Besides target mRNAs profile, epigenetic regulation   
and abnormalities in miRNA-processing genes and proteins  
are two important influential factors for miRNAs expression  
[60]. Several groups have verified that DNA hypomethyla- 
tion, CpG island hypermethylation and histone-modification  
could affect miRNA expression. As microRNAs biogenesis  
is essential for the expression levels of miRNAs, alterations  
in the miRNA processing machinery definitely will result in  
dramatic effects on miRNAs expression. Essential proteins  
take part in miRNAs biogenesis, such as Drosha and Dicer,  
may contribute to aberrant miRNAs expression [60].  
Table 1.  Functions of Some Critical Targets of The miR-17-
92 Cluster 
Name Function 
E2Fs  Positive regulators of cell proliferation, 
Proapoptotic proteins [42, 43] 
CDKN1A (p21)  Negative regulator of G1-S checkpoint [46, 47] 
BIM  Proapoptotic protein [46, 47] 
Tsp1  Anti-angiogenic protein [49, 50] 
CTGF  Anti-angiogenic protein [49, 50] 
AIB1  Oncogenic protein [59] 
Cyclin D1  Oncogenic protein [60] 
 
POTENTIAL USES OF THE ONCOMIRS IN CANCER 
DIAGNOSIS, THERAPY AND PROGNOSIS 
  The most commonly used high-throughput technique for 
miRNA profiling is oligonucleotide miRNA microarray 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The interactions among c-Myc, E2Fs and the miR-17-
92 cluster. Arrows indicate induction of gene expression. Bidirec-
tional arrows refer to mutual transcriptional induction. Hammer-
heads indicate translational inhibition or degradation of mRNAs 
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analysis. Liu et al. firstly reported the process for genome-
wide miRNA profiling in human and mouse tissues [61]. Lu 
et al. reported that a bead-based flow cytometric miRNA 
expression profiling method could accurately reflect the de-
velopmental lineage and differentiation state of the tumors 
[62]. Based on the use of locked nucleic acid (LNA)-
modified oligonucleotides, researchers developed a microar-
ray platform (miChip) displays superior sensitivity [63]. 
These researches are crucial in providing novel insights into 
cancer diagnosis using microRNA profiling. Taking advan-
tage of these high-throughput platforms, miRNA expression 
profiling have been widely studied in human cancers, includ-
ing solid tumors and hematopoietic malignancies [64]. 
  The discovery of oncomirs is likely to introduce novel 
approaches using miRNA therapy to treat cancers. Designing 
antisense oligonucleotides that are complementary to mature 
oncogenic miRNAs might inactivate the miRNAs and lead to 
inhibition of tumor growth. These synthetic oligonucleotides 
are termed as anti-miRNA oligonucleotides (AMOs). Ma-
tsubara et al. reported that using AMOs, they successfully 
induced apoptosis selectively in lung cancer cells overex-
pressing miRNAs of the miR-17-92 cluster [65]. Krützfeldt 
et al. reported antagomirs, which are chemically engineered 
oligonucleotides, are powerful tools to silence specific miR-
NAs in vivo [66]. These findings might ultimately lead to 
future translation into clinical applications. On the other 
hand, as to oncomirs function as tumor suppressors, tech-
niques to overexpress these miRNAs could be used to treat 
certain tumour types. These miRNAs could be delivered by 
virus or liposomes of transient expression systems [31]. 
 Takamizawa  et al. identified that reduced expression of 
the  let-7 microRNAs in human lung cancers is associated 
with shortened postoperative survival [34]. Yanaihara et al. 
found high expression of miR-155 and low expression of let-
7a-2 are correlated with poor survival in lung adenocarcino-
mas [67]. Prognostic value of microRNA expression profil-
ing in breast cancer has also been demonstrated by Iorio and 
colleagues [68]. A paper recently published in Cancer Re-
search reported that microRNA signatures were superior in 
predicting overall survival in squamous cell carcinoma 
(SCC) patients than previous mRNA-based signatures. This 
research further highlights potential clinical value of these 
novel biomarkers in cancer prognosis [69]. 
PERSPECTIVE 
  Studying the oncomirs is helpful in understanding the 
whole regulation network of initiation and progression of 
cancers, and new findings in the field could be promising 
ways in diagnosis, therapy and prognosis. However, treating 
cancers by taming these miRNAs need more efforts. The 
fundamental mechanisms require more detailed elaborations, 
target mRNAs have to be highly specific, and more effective 
small RNA delivery systems have to be introduced. Taken 
together, from lab bench to clinical bed, there is still a long 
way to go. 
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